Hemant S. Murthy MD
@hemant_murthy
Hematology/Oncology @MayoCancerCare #mayoclinicfl CAR-T, Stem Cell Transplantation, Palliative Care, Tweets opinions are mine #bmtsm #tcellrx #cartcelltherapy
Honored to be promoted to Professor of Medicine at @MayoClinic. Grateful for the support and belief from friends, colleagues, mentors, teachers and so so many people. Thankful for my family for their continued love and encouragement, allowing me to pursue my career!
.@DrHKantarjian is an absolute legend who bettered the lives of thousands of patients & mentored (directly or indirectly) a huge number of leukemia doctors across 🌎 . He always pushed the envelope to advance cutting edge research & challenged the dogma, often proven right.
It saddens and surprises me to see this - A legend @DrHKantarjian who has changed how we approach leukemia forever is stepping down. A blog by @lenzwelling just out. lenzwelling.com/2025/06/an-emb…
This is a huge finding. I hate keeping patients NPO all day, just to have the OR cancel my case at 3pm. Turn out we don’t actually need them to be NPO. Chances anesthesia groups will sign on to this? Zero. Why would they? That’s one less reason they can cancel a case.
NO ASSOCIATION BETWEEN PREPROCEDURAL FASTING AND WITNESSED PULMONARY ASPIRATION A SYSTEMATIC REVIEW AND META-ANALYSIS I want to bring to everyone's attention the publication of an article we have been working on for some time. Ever been annoyed by having cases cancelled because…
Along with collaborators at @UTSWMedCenter we report a study in the @NEJM on the potential role of monoclonal anti-PF4 abs in recurrent miscarriage. Larger studies to follow! @MayoClinic @mayocliniclabs nejm.org/doi/full/10.10…
Have been working w/ @Jmarksloan on this for a decade: BV-CHEP for 1L ATLL. @BrJHaem N=16 CR: 62.5% ORR: 87.5% mOS: 15.7m AlloSCT: 5 pts; mOS: NR Tox: cytopenias, mucositis, PN New consideration for aggressive ATLL. onlinelibrary.wiley.com/doi/epdf/10.11…
Inspired by her daughter, Roxana Dronca, M.D., helped create a program that brings life-saving cancer treatment directly to patients’ homes. mayocl.in/46vfxRb
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet thelancet.com/journals/lance…
Sharing our work to help our CAR T-cell therapy pts, vaccine response varies by antigen: ✅ 100%: Polio & Tetanus 🟡 ~50%: Hepatitis A/B, Varicella 🔴 Only 33%: Pneumococcus 📊 Higher IgA levels = better response Read the full study → doi.org/10.1038/s41408… #CAR_T #Vaccination
We are proud to unveil the Mayo Clinic Berg Innovation Exchange — a major step in transforming global healthcare, made possible by the generosity of Gilchrist & Amy Berg. Learn more: mayocl.in/44FtyKN #HealthcareInnovation #MayoClinic
Today Mayo Clinic announced a transformative philanthropic gift from Gilchrist and Amy Berg to support the newly named Mayo Clinic Berg Innovation Exchange. Read more: newsnetwork.mayoclinic.org/discussion/tra…
FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies | FDA fda.gov/vaccines-blood…
Patients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity. ow.ly/tEXM50W7tLk #myeloidneoplasia #transplantation #clinicaltrialsandobservations
Cancer patients are dying after choosing fad social media ‘cures’ thetimes.com/uk/healthcare/…
Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR ashpublications.org/bloodadvances/…
Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo • if in PR, allo appears preferable • no impact on source of allo cells I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm
Safety in a hybrid hospital‐at‐home program versus traditional inpatient care: A pragmatic randomized controlled trial - Maniaci - Journal of Hospital Medicine - Wiley Online Library @MayoClinic …mpublications.onlinelibrary.wiley.com/doi/10.1002/jh…
A Cutting-Edge Cancer Therapy Offers Hope for Patients With Lupus nytimes.com/2025/06/18/wel… via @NYTimes
Happy to share the first @AjHematology #BPDCNsm comprehensive annual review and guidance for BPDCN. Thankful to my colleagues @LuskinMarlise @n_gangat @angelamferaco Nicole LeBoeuf and @lane_andy onlinelibrary.wiley.com/doi/10.1002/aj…
Fascinating talk by DeSelm - CAR-T worked less well on tumours not irradiated. Irradiation reduces phosphethalamine which increases DAG in CAR-T, promoting cell function. #ICML2025
Top Oncologists from @EHA_Hematology 2025. Explore the latest updates from #EHA2025: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @FadiHaddad_MD | @Eddie_Cliff | @calliecoombsmd | @TalhaBadarMD | @GuiperiniMD |…
Excited to share findings from the multicenter ACCESS trial, supported by @CIBMTR & @nmdp_org . PTCy-based GVHD prophylaxis improved survival after MMUD HCT. Grateful for this collaboration advancing equitable transplant access. #ADonorForAll ascopubs.org/doi/10.1200/JC…